Corcept's Stock Plummets After FDA Rejection
Update: 2026-01-01
Description
Corcept Therapeutics stock plummeted over fifty percent following the FDAs rejection of their new drug application for relacorilant, intended to treat high blood pressure in patients with hypercortisolism. The FDA cited insufficient data to prove the drugs benefits outweighed its risks, disappointing investors who had high hopes based on earlier phase three results. The rejection has raised concerns about more expensive trials and dampened investor confidence in the companys short-term plans. Checkout Solipillow.com
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
